Impact of selective prostaglandin E1 treatment on graft perfusion and function after liver transplantation

Hepato-Gastroenterology

Volumn 51, Issue 56, 2004, Pages 526-531

  Kornberg, A ^a   Schotte, U ^a   Kupper, B ^a   Hommann, M ^a   Scheele, J ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Hepatic artery resistive index; Liver transplantation; Prostaglandin E1

Indexed keywords

PROSTAGLANDIN E1;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; FEMALE; GRAFT FAILURE; GRAFT NONFUNCTION; GRAFT SURVIVAL; HEPATIC ARTERY; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER ISCHEMIA; LIVER PERFUSION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REPERFUSION INJURY; TREATMENT OUTCOME; VASCULAR RESISTANCE;

ADULT; ALANINE TRANSAMINASE; ALPROSTADIL; FEMALE; GLUTAMATE DEHYDROGENASE; HEPATIC ARTERY; HUMANS; LENGTH OF STAY; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; REPERFUSION INJURY; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 1842430900     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Shaw SW, Gordon RD, Iwatsuki S, Starzl TE: Hepatic retransplantation. Transplant Proc 1987; 19:3261.
2. St Cyr JA, Elick B, Freese D, et al: Use of triple therapy and percutaneous needle biopsy to minimize graft failure following liver transplant. Transplant Proc 1987; 19:264.
3. Otto G, Wolff H, Uerlings I, Gelbert K: Preservation damage in liver transplantation. Transplantation 1986; 42:122.
4. Flynn JT: The effect of arachidonic acid on the response of the isolated liver to hypoxia. Adv Shock Res 1979; 1:191.
5. Araki H, Lefer AM: Cytoprotective effect of prostacyclin during hypoxia in the isolated perfused cat liver. Fed Proc 1979; 38:5093.
6. Sinclair SB, Greig PD, Blendis LM, et al: Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E1. Clin Invest 1989; 84:1063.
7. Flowers M, Sherker A, Sinclair SB, et al: Prostaglandin E in the treatment of recurrent hepatitis B infection after orthotopic liver transplantation. Transplantation 1994; 58:183.
8. Greig PD, Woolf GM, Sinclai SB, et al: Treatment of primary liver graft non-functioning with prostaglandin E1. Transplantation 1989; 48:447.
9. Quiroga J, Prieto J: Liver cytoprotection by prostaglandins. Pharmac Ther 1993; 58:67.
10. Kaisers U, Neumann U, Kuhlen U, et al: Nitroglycerin versus epoprostenol: effects on hemodynamics, oxygen delivery, and hepatic venous oxygenation after liver transplantation. Liver Transplant Surg 1996; 2:455.
11. Richardson PD, Withrington PG: The vasodilator actions of isoprenaline, histamine, PGE2, glucagon and secretion on the hepatic arterial vascular bed of the dog. Br J Pharmacol 1978; 48:337.
12. Klein AS, Cofer JB, Pruett TL, et al: Prostaglandin E1 administration following orthotopic liver transplantation: A randomized prospective multicenter trial. Gastroenterology 1996; 111:710.
13. Henley KS, Lucey M, Normolle DP, et al: A double-blind randomized placebo-controlled trial of prostaglandin E1 in liver transplantation. Hepatology 1993; 21:366.
14. Neumann UP, Kaisers U, Langrehr JM, Lang M, et al: Treatment with PGE1 in patients after liver transplantation. Transplant Proc 1998; 30:1869.
15. Ploeg RJ, D'Alessandro AM, Knechtle SJ, et al: Risk factors for primary dysfunction after liver transplantation - a multivariate analysis. Transplantation 1993; 55:807.
16. McKeown CMB, Edwards V, Phillips MJ, Harvey PRC, Petrunka CN, Strasberg SM: Sinusoidal lining cell damage: the critical injury in cold preservation of liver allografts in the rat. Transplantation 1988; 46:178.
17. Noda Y, Fukuoka K, Morimoto H, et al: Protective effect of prostaglandin E1 on D-galactoasamine-HC1 induced liver cell necrosis in the rabbit. Scand J Gastroenterol 1982; 17:43.
18. Robert A, Nexamis JE, Lancaster C, et al: Gastric cytoprotective properties of prostaglandins. Gastroenterology 1977; 77:1121.
19. Miura Y, Fukui N: Prostaglandins as possible triggers for liver regeneration after partial hepatectomy: a review. Cell Mol Biol 1979; 25:179.
20. Goldyne ME, Stobo JD: Immunregulatory role of prostaglandins and related lipids. Crit Rev Immunol 1981; 2:189.
21. Goodwill JS, Webb DR: Regulation of the immune response by prostaglandins. Clin Immunol Immunopathol 1980; 15:5.
22. Feely J, Wood AJ: Reduction in apparent liver blood flow in man by histamine receptor blockers and inhibition of prostaglandin synthesis. Br J Clin Pharmacol 1981; 13:592.
23. Hossain MA, Hamamoto J, Wakabayashi H, et al: Experimental study of the effect of intraportal prostaglandin E1 on hepatic blood flow during reperfusion after ischaemia and hepatectomy. Br J Surg 1999; 86:776.
24. Lefer AM: Eicosanoids as mediators of schemia and shock. Fed Proc 1985; 44:275.
25. Gaber AO, Thistlethwaite JJ, Busse HS, et al: Improved results of preservation of hepatic grafts perfused with albumin and prostaglandins. Transplant Proc 1988; 20:992.
26. Hamazaki K, Kuroda T, Kajikawa S, Amano J: Prostaglandin E1 reduces thromboxan A2 in hepatic ischemia-reperfusion. Hepatogastroenterology 2000; 47:807.
27. Fantone JC, Kinnes DA: Prostaglandin E1 and prostaglandin 12 modulation of superoxide production by human neutrophils. Biochem Biophys Res Commun 1983; 113:506.
28. Tasaka H, Suehiro T, Wakiyama S, Yanaga K, Shimada M, Sugimachi K, Itasaka H, Suehiro T, Wakiyama S, Yanaga K, et al: The mechanism of hepatic graft protection against reperfusion injury by prostaglandin E1. Surg Today 1999; 29(6):526-532.
29. Makowka L, Lopatin W, Gilas T, et al: Prevention of cyclosporine (CyA) nephrotoxicity by synthetic prostaglandins. Clin Nephrol 1986; 25:89.
30. Tobimatsu M, Konomi K, Saito S, Tsumayari T: Protective effect of prostaglandin E1 on ischemic induced acute renal failure in dogs. Surgery 1985; 98:45.
31. Flowers M, Sherker A, Sinclair SB, et al: Prostaglandin E1 treatment of recurrent hepatitis B infection after orthotopic liver transplantation. Transplantation 1994; 58:183.
32. Takaya S, Doyle H, Todo S, Irish W, Fung JJ, Strazl TE: Reduction of primary nonfunctioning with prostaglandin E1 after clinical liver transplantation. Transplant Proc 1995; 27:1862.
33. Harms J, Ysebaert D, Ringe B, Gebel M, Pichlmayr R: The diagnostic value of quantitative Doppler ultrasound signal analysis in diagnosis of postoperative organ dysfunction following orthotopic liver transplantation. Vasa Suppl 1991; 33:84.
34. Dodd GD 3rd, Memel DS, Zajko AB, Baron RL, Santaguida LA: Hepatic artery stenosis and thrombosis in transplant recipients: Doppler diagnosis with resistive index and systolic acceleration time. Radiology 1994; 192:657.
35. Platt JF, Rubin JM, Ellis JH: Hepatic artery resistance changes in portal vein thrombosis. Radiology, 1995; 196:95.
36. Propeck PA, Scanlan KA: Reversed or absent hepatic arterial diastolic flow in liver transplants shown by duplex-sonography: A poor predictor of subsequent hepatic artery thrombosis. AJR 1992; 159:1199.
37. Harms J, Ringe B, Pichlmayr R: Postoperative liver allograft dysfunction: the use of quantitative duplex Doppler signal analysis in adult liver transplant patients. Bildgebung 1995; 62(2):124-131.
38. Kornberg A, Grube Th, Wagner Th, et al: Differentiated therapy with prostaglandin E1 (Alprostadil) after orthotopic liver transplantation: the usefulness of procalcitonin (PCT) and hepatic artery resistive index for the evaluation of early graft function and clinical course. Clin Chem Lab Med 2000; 38:1177.
39. Pham PT, Pham PC, Wilkinson AH: The kidney in liver transplantation. Clin Liver Dis 2000; 4:567.
40. Richardson D: Dialysis in non-renal organ (liver) transplantation. Nephron 2001; 88:296.
41. Tancharoen S, Jones RM, Angus PW, Hardy KJ: Beneficial effect of prostaglandin E1 on hepatic allograft rejection following orthotopic liver transplantation. Transplant Proc 1993; 25:2890.